Why Aurinia Pharmaceuticals Stock Is Surging Monday Morning

Benzinga_recent_news03-23

The company said Kevin Tang, Aurinia's chair of the board, will succeed Peter Greenleaf as CEO, while Greenleaf will remain on as a consultant to support the transition. The market appeared to welcome...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2621702848?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/23/Doctor-holding-digital-tablet-at-meeting.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2026-03-23 22:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621702848","market":"hk","top_or_hot":-1,"title":"Why Aurinia Pharmaceuticals Stock Is Surging Monday Morning","media":"Benzinga_recent_news","content":"<div>\n<p>The company said Kevin Tang, Aurinia's chair of the board, will succeed Peter Greenleaf as CEO, while Greenleaf will remain on as a consultant to support the transition.\nThe market appeared to welcome...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/movers/26/03/51407731/why-aurinia-pharmaceuticals-stock-is-surging-monday-morning\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Aurinia Pharmaceuticals Stock Is Surging Monday Morning</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Aurinia Pharmaceuticals Stock Is Surging Monday Morning\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-23 22:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/trading-ideas/movers/26/03/51407731/why-aurinia-pharmaceuticals-stock-is-surging-monday-morning><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The company said Kevin Tang, Aurinia's chair of the board, will succeed Peter Greenleaf as CEO, while Greenleaf will remain on as a consultant to support the transition.\nThe market appeared to welcome...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/movers/26/03/51407731/why-aurinia-pharmaceuticals-stock-is-surging-monday-morning\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/03/51407731/why-aurinia-pharmaceuticals-stock-is-surging-monday-morning","article_id":"2621702848","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/23/Doctor-holding-digital-tablet-at-meeting.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/26/03/51407731/why-aurinia-pharmaceuticals-stock-is-surging-monday-morning","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2621702848","pubTimestamp":1774275960,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Aurinia Pharmaceuticals shares are trading higher Monday after announcing a leadership transition seen as a sign of continuity and strategy.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","AUPH":"Aurinia Pharmaceuticals Inc"},"translate_title":"为什么Aurinia Pharmaceuticals股价周一上午飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AUPH":1.5},"content_text":"The company said Kevin Tang, Aurinia's chair of the board, will succeed Peter Greenleaf as CEO, while Greenleaf will remain on as a consultant to support the transition.\nThe market appeared to welcome the shakeup, with the announcement emphasizing that Aurinia remains in a strong position operationally. Tang credited Greenleaf's stewardship during his seven-year tenure and said Lupkynis is continuing to emerge as a standard therapy for lupus nephritis. He also pointed to progress in the company's pipeline, highlighting aritinercept as it advances through clinical studies.\nAlongside the CEO change, Aurinia announced several executive appointments, including Ryan Cole as COO, Michael Hearne as CFO and Thomas Wei as CSO. \nStew Kroll and Stephen Robertson will remain in their current roles, suggesting broader stability across the leadership team even as the company reshapes top management.\nFor investors, the move may signal an effort to sharpen execution around both commercial growth and pipeline development. Aurinia's core business remains centered on Lupkynis, the first FDA-approved oral therapy for adults with active lupus nephritis, while aritinercept represents a potential longer-term catalyst in autoimmune disease treatment.\nAUPH's RSI has mostly traded in the neutral range over the past year, with intermittent dips toward oversold levels and multiple stretches pushing into overbought territory above 70. \nRecently, RSI has cooled back toward the mid-range after prior overbought periods, indicating fading momentum following earlier strength.\nAUPH Price Action: Aurinia Pharmaceuticals shares were up 5.06% at $14.74 at the time of publication on Monday, according to Benzinga Pro data.\nImage: Adobe Stock Images\nThis content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.\nTo add Benzinga News as your preferred source on Google, click here.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621702848","isCrawlerRequest":true}